Channel
허혜민의 제약/바이오 소식통
@huhpharm
Created July 12, 2020Advertised since May 2026
KO · 한국어Sponsored-eligible
제약/바이오 뉴스, 업데이트, 발간자료 공유
Members
24,163
Avg. views
1,933
CPM (est.)
—
Ads indexed
30
Updated: 2026-08-25
Cashier signals
Paid media
Yes
Paid messages
Yes
Star gifts
1
Alert via Telegram BotWeb alerts on tgads.observertgads.observerFull audience & growth statstelegramstats.netHow to advertise in this nichetgads.net
Ad niches in this channel
Top advertisers in this channel
- 20@trading_kim_minjun@trading_kim_minjun
- 8@story_parkpro@story_parkpro
- 5@coinsignala@coinsignala
- 5@kangdongwona@kangdongwona
- 4@futures_alt@futures_alt
- 4@sergprofx_bot@sergprofx_bot
- 3@hyuns_room@hyuns_room
- 3@dooridoory@dooridoory
Activity
04-1319 weeks08-24
Recent posts
- 2026-09-05
Media post
816 viewsOpen in Telegram - 2026-09-05
올해 M&A 상위 인수 기업 순위 출처: PersimmonTI
876 viewsOpen in Telegram - 2026-09-05
Media post
1,854 viewsOpen in Telegram - 2026-09-05
[키움 허혜민] WCLC 2026, Summit ivonescimab OS에서 두 번의 긍정적 결과 Summit Therapeutics의 ivonescimab(PD-1×VEGF) 관련 2개 3상에서 전체생존기간(OS) 긍정적 업데이트. Summit 주가 목요일 +17%. 세부 데이터는 WCLC에서 공개 예정 먼저 HARM…
1,839 viewsOpen in Telegram - 2026-09-05
[키움 허혜민] Novartis Lp(a) 치료제 3상 실패. Lp(a)는 낮췄지만 심혈관 사건 감소로 이어지지 않음 Novartis, pelacarsen의 Lp(a)HORIZON 3상에서 1차 평가지표 미충족 발표. Pelacarsen은 Ionis로부터 도입한 Lp(a) 생성 억제 ASO(안티센스 올리고뉴클레오타이드) …
3,283 viewsOpen in Telegram - 2026-09-04
안녕하세요, 한미 IR그룹입니다. 한미약품이 오는 9월 8일, 유럽소아내분비학회(ESPE 2026)에서 희귀질환 선천성 고인슐린증 치료제 에페거글루카곤의 글로벌 임상 2상 연구 내용을 구두 발표합니다. 에페거글루카곤은 세계 최초 주 1회 투여 제형으로 개발 중인 지속형 글루카곤 작용제로, 현재 글로벌 임상 2상의 핵심투여…
2,723 viewsOpen in Telegram - 2026-09-04
오스코텍(039200) 투자판단관련주요경영사항(임상시험결과) (알츠하이머 치료 후보물질 ADELY01 임상 1a/1b상 임상시험결과보고서(CSR) 수령) 📌 제목 알츠하이머 치료 후보물질 ADEL-Y01 임상 1a/1b상 임상시험결과보고서(CSR) 수령 📌 내용 - 임상시험단계 : 임상 1a/1b - 임상시험승인기관 …
2,449 viewsOpen in Telegram - 2026-09-04
코스닥 침체이긴 하죠.. 9/2일 기사 참고 https://view.asiae.co.kr/article/2026090209312996427
2,928 viewsOpen in Telegram
Research from the blog
All →- 2026-05-07
AvaTrade Telegram Ads Profile: How AvaTrade Advertises in 2026
How AvaTrade runs sponsored Telegram campaigns in 2026 — creative formats, regional strategy, and what the tgadsspy archive reveals about this forex broker.
- 2026-05-07
Exness Telegram Ads Profile: How Exness Advertises in 2026
How Exness runs sponsored Telegram campaigns in 2026 — creative formats, regional strategy, and what the tgadsspy archive reveals about this forex broker.
- 2026-05-07
FP Markets Telegram Ads Profile: How FP Markets Advertises in 2026
How FP Markets runs sponsored Telegram campaigns in 2026 — creative formats, regional strategy, and what the tgadsspy archive reveals about this forex broker.
- 2026-05-07
IC Markets Telegram Ads Profile: How IC Markets Advertises in 2026
How IC Markets runs sponsored Telegram campaigns in 2026 — creative formats, regional strategy, and what the tgadsspy archive reveals about this forex broker.
Sponsored impressions seen in this channel · EUR cabinet
Flags — the regions we asked our observer pool for while recording this ad in this channel. That is a label on our request, not a confirmed place of viewing: when no account is available in the requested country the pool silently substitutes another and does not say so. It is not the advertiser's targeting country either. We stopped requesting the region on {date}, so newer creatives carry no flags at all. The channel's main country (by its language) is highlighted in blue; regions under 5% are collapsed into +N.
- ×32026-09-01 → 2026-09-02
- ×32026-08-31 → 2026-09-01
- ×22026-09-04 → 2026-09-05
- ×22026-09-01 → 2026-09-04
- ×22026-09-03
- ×22026-08-31 → 2026-09-01
- ×22026-09-01
- ×12026-09-05
- ×12026-09-05
- ×12026-09-05
- ×12026-09-03
- ×12026-09-03
- ×12026-09-03
- ×12026-09-03
- ×12026-09-02
- ×12026-09-01
- ×12026-09-01
- ×12026-09-01
- ×12026-08-31
- ×12026-08-30
- ×12026-08-30
혼자 잃지 말고 전문가와 1:1로 함께 수익 내세요 💶 당장 여기서 시작하세요 
우리 팀에 합류하세요 👇🏻
